著者
檜山 英三 原田 隆範 兒島 正人
出版者
一般社団法人 日本質量分析学会
雑誌
Journal of the Mass Spectrometry Society of Japan (ISSN:13408097)
巻号頁・発行日
vol.68, no.2, pp.33-37, 2020-04-01 (Released:2020-04-15)
参考文献数
2

Circulating tumor cell (CTC) has improved the study of cancer disease as it represents a noninvasive biopsy that can be used as prognostic and prediction biomarkers as well as for future molecular diagnosis as an accurate selection of molecular targets and effective drugs. As tumor heterogeneity exists in neuroblastoma (NBL), we aimed to evaluate lipid-metabolomic molecular profile as well as genetic profiles at the single cell level of CTC for better understanding the heterogeneity and malignant grade of NBL. For attempt of CTC analysis in NBL patients, we have isolated single-CTCs and then performed direct trapping of a single cell within a nanospray tip followed by super-sonication after the addition of ionization solvent for metabolomics analysis. And we also performed genomic aberrations and expressions using next-generation sequencing after whole genome/transcriptome amplifications (WGA/WTA). In the NBL-CTCs, metabolomic analysis detected catechol amine metabolites, which are specific to NBL, and drugs included in the patient’s course of therapy in addition to vital molecules such as amino acids. In genomic analysis, the average amount of amplified DNA was 19.0 µg, and the percentage of reads mapped to any targeted region relative to all reads mapped to the reference was 66.5–98.9%. The concordance rates of CTC and tumor mutations were 49–80%. The genomic expression analysis in CTC showed the activation of cancer metastatic, neurogenic, stem cell signaling pathway genes. This “direct single-cell analysis method” seems to be useful for direct and wide range genomic and molecular marker detection in NBL-CTC, for evaluating heterogeneity of NBL tumor at diagnosis as well as during treatments. This method will be applicable for selection of effective drugs and evaluation of treatment efficacy in future.
著者
市川 徹 横山 隆 檜山 英三 松浦 雄一郎
出版者
特定非営利活動法人 日本小児外科学会
雑誌
日本小児外科学会雑誌 (ISSN:0288609X)
巻号頁・発行日
vol.31, no.5, pp.732-738, 1995
被引用文献数
2

広島大学第一外科において経験した小児期に初回手術を受けた先天性胆道拡張症(CBD)24例を一期的分流手術後3年以上経過例14例,初回内瘻術後再手術例4例,初回外瘻術(うち3例は胆道穿孔合併)後分流手術例6例に分け術後経過,合併症を術式別に検討した.一期的分流手術例では術後短期間膵炎や胆管炎症状を認めるものや,術後数年間肝内胆管拡張を認めるものも有るが徐々に軽減しており概ね問題は無い.胆道穿孔合併例や,初回胆管炎や膵炎が内科的にコントロールできないものには,初回胆汁外瘻造詮術を行い合併症予防のために有用であった.二期的分流手術後の術後経過も一期的分流手術例に比し差を認めず良好であった,これに対し初回内瘻造般例は,その後全例重篤な胆管炎を起こし,2年から15年後に分流手術を要しており,たとえ無症状でも早期に分流手術を行うべきである. CBD の分流手術にあたっては胆汁の充分なドレナージは当然必要であるが,膵管内 protein plug や結石を認め更に膵液流出障害が考えられる場合は膵液ドレナージ術の付加も考慮すべきである.